John ­McCamant

John ­McCamant, editor of Medical Technology Stock Letter, Berkeley, California. Its model portfolio returned an annualized 39% over five years, compared with 14% for the S&P 500 stock index. BioInvest.com

Portfolio Strategy

Investments that Are Worth the Risk for Higher Returns

As the bull market ages some investors are stretching their comfort zones to boost returns. Here are some great investments options to do that.

Stocks

5 Biotech Stocks That Could Become Blockbusters

Pharmaceutical giants are rushing to partner with or acquire small biotechs, providing a big opportunity for investors.

Stocks

5 Stocks That Could Soar from Blockbuster Drugs

Many investors stop looking for opportunities in tumultuous markets. They become paralyzed and make no changes at all in their…

Stocks

The Next Big Drug

The odds are stacked against biotech investors. It typically takes at least 10 years and $500 million in funding to…

Stocks

How to Invest in Cancer Breakthroughs

Four stocks with great promise Hundreds of US companies are trying to develop compounds to attack cancer in innovative ways…